Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling

INTRODUCTION: Elagolix is approved for the management of moderate-to-severe pain associated with endometriosis. The aim of this analysis was to develop a physiologically based pharmacokinetic (PBPK) model that describes the enzyme-transporter interplay involved in the disposition of elagolix and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiney, Manoj S., Ng, Juki, Gibbs, John P., Shebley, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217817/
https://www.ncbi.nlm.nih.gov/pubmed/31713224
http://dx.doi.org/10.1007/s40262-019-00833-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217817/
https://www.ncbi.nlm.nih.gov/pubmed/31713224
http://dx.doi.org/10.1007/s40262-019-00833-6

Ejemplares similares